Archive | Conferences

Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma

Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma

Encorafenib (Braftovi) plus binimetinib (Mektovi) show sustained overall survival (OS) and progression-free survival (PFS) benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS (NCT01909453) study, presented in a poster at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated continuing benefit in overall survival (OS) and progression-free survival (PFS) for patients with BRAF V600—mutant melanoma, according to an updated analysis of the COLUMBUS (NCT01909453) trial during a poster presentation at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Autologous Tumor-Infiltrating Lymphocytes Effective for Treatment of Metastatic Melanoma

Lifileucel (LN-144) showed a favorable overall response rate in patients with pretreated metastatic melanoma, according to initial data from cohort 4 of the phase 2 C-144-01 trial.

Read the full story

Posted in Melanoma News, Health Professionals, Conferences